Top Buy Stocks
Sign In
Invest in GRFS
$9.74
-0.0100 (-0.103%)
At Close: Jul 11, 2025
XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology
05:00am, Tuesday, 10'th Jun 2025
Freising, Germany, June 10, 2025 — XL-protein GmbH, a pioneer in the area of biopolymers for pharmacokinetic optimization, announced today that it has entered into a worldwide License, Development a
Grifols (GRFS) Is Up 2.47% in One Week: What You Should Know
01:01pm, Thursday, 05'th Jun 2025
Does Grifols (GRFS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Grifols (GRFS) Stock Undervalued Right Now?
10:46am, Tuesday, 03'rd Jun 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
GRFS vs. STVN: Which Stock Is the Better Value Option?
12:46pm, Monday, 02'nd Jun 2025
Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Stevanato Group (STVN). But which of these two stocks offers value investors a better bang fo
Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting
04:05pm, Friday, 30'th May 2025
NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. (“Grifols” or the “Company�
US court finds enough evidence to proceed with Grifols lawsuit against Gotham City
03:15am, Friday, 30'th May 2025
A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company Grifols against short seller Gotham City Research, Grifols said in a statement on
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?
11:06am, Wednesday, 28'th May 2025
At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.
Grifols: If This Works Out, It Has Massive Upside
12:09pm, Thursday, 22'nd May 2025
Grifols offers compelling long-term upside, with potential returns exceeding 200% as the company recovers and grows earnings. Recent Q1 2025 results confirm strong operational recovery: top-line growt
GRFS or NBIX: Which Is the Better Value Stock Right Now?
12:46pm, Thursday, 15'th May 2025
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Grifols (GRFS) and Neurocrine Biosciences (NBIX). But which of these two stocks presents investors with th
Grifols, S.A. (GRFS) Q1 2025 Earnings Conference Call Transcript
04:51pm, Monday, 12'th May 2025
Grifols, S.A. (NASDAQ:GRFS ) Q1 2025 Earnings Conference Call May 12, 2025 12:30 PM ET Company Participants Danny Segarra - VP, IR and Sustainability Nacho Abia - CEO Rahul Srinivasan - CFO Roland Wan
Grifols says on course to meet 2025 outlook as net profit triples
02:47pm, Monday, 12'th May 2025
Grifols's net profit almost tripled from a year earlier, which the Spanish drugmaker said reinforced its confidence in meeting its full-year guidance.
IBL International collaborates with Grifols on advanced biomarker panels
09:29am, Tuesday, 08'th Apr 2025
MÄNNEDORF, Switzerland--(BUSINESS WIRE)--IBL International GmbH, a Tecan company, which develops, manufactures and offers specialty diagnostics, today announced a strategic partnership with Grifols,
Brookfield resumes Grifols takeover talks, El Confidencial reports
03:03am, Wednesday, 02'nd Apr 2025
Canadian investment fund Brookfield has resumed talks on a potential takeover of Spanish pharmaceuticals company Grifols four months after a previous attempt fell through, news website El Confidencial
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale
12:58pm, Thursday, 27'th Feb 2025
Grifols remains a strong long-term investment due to its leading position in the plasma industry and improving financial fundamentals, despite short-term volatility and lack of a dividend. The company
Grifols expects to boost revenue and free cash flow, shares soar
11:23am, Thursday, 27'th Feb 2025
Spanish drugmaker Grifols said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in the coming years as it aims to leave behind a tumultuous 2024 when it lost
